Express Pharma
JUNE 13, 2024
billion in 2029, forecasts GlobalData. Pharmaceutical companies have an opportunity to educate physicians both specialists and primary care physicians alike, about the indication and early warning signs.” The key opinion leaders (KOLs) interviewed by GlobalData identified the greatest unmet needs within the ALS space.
European Pharmaceutical Review
JUNE 26, 2024
This is compared to the company’s $3.9 (DKK Completion is expected between 2027 and 2029. Currently, worldwide, the pharmaceutical company has a five production sites in Denmark, US, France, Brazil and China, the company noted. billion investment appeared first on European Pharmaceutical Review.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 10, 2023
This marks a significant development in a tumultuous dispute between the pharmaceutical company and the US government. In November 2019, the government sued Gilead over the company’s alleged patent infringement of the two PrEP drugs Descovy and Truvada. GlobalData is the parent company of Pharmaceutical Technology.
Express Pharma
JULY 23, 2024
We appreciate that the Government of India has reiterated the importance and necessity of Patient Assistance Programmes (PAP) offered by the pharmaceutical industry to improve access to life-saving drugs by extending the customs duty waiver on drugs and medicines imported to India for the supply under PAP through to March 31, 2029.
Express Pharma
OCTOBER 16, 2024
Nawab concludes, “While the COPD market is projected to grow strongly in the forecast period, potential barriers to this growth include loss of exclusivity within the forecast period, and the introduction of the $35 inhaler cap in the US observed by several pharmaceutical companies in the US.
Express Pharma
OCTOBER 16, 2024
Similarly, India’s pharmaceutical contract manufacturing market is expected to increase at a CAGR of 14.67 billion by 2029 (3). Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceutical companies. billion by 2030 (2).
Pharmaceutical Technology
JANUARY 10, 2023
billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.
Expert insights. Personalized for you.
98 
Let's personalize your content